This is research, not a buy or sell recommendation. Robo-advice in Taiwan requires an FSC licence; FEAF analyses, explains and monitors, and the investor makes the decision. Judgement thresholds are working rules pending review by the team's finance members.
Plain-language summary of valuation, growth, profitability, balance sheet, and recent MOPS filings.
Your risk profile
Conclusion
Mixed picture: 2 strengths against 3 watch-outs. Weigh them against your own goals.
Points to watch for a moderate profile: see the items marked above.
In plain words
Stock 1711 presents a mixed picture, carrying a P/E of 103.97 which is well above the Chemicals median of 18.46 across 26 listed peers. Revenue fell -7.3% in 2025, though the latest quarter Q3 2026 grew 27.4% year on year. Profitability shows a weak return on equity of 2.1% and a 2.3% net margin, alongside a light debt load of 35.5% of total assets in Q3 2026 and positive 2025 free cash flow of 312 NT$ million. Ultimately, the final decision rests with the investor.
Written by gemini-3.6-flash from the facts above; every number was checked against them.Strengths
+
Liabilities are only 35.5% of total assets (Q3 2026): a light debt load. source (Financials) →
+
Free cash flow was positive in 2025: 312 NT$ million. source (Financials) →
Watch-outs
!
P/E 103.97 is well above the Chemicals median of 18.46 (26 listed peers): priced richer than peers. source (Key Stats) →
!
Revenue fell -7.3% in 2025; latest quarter Q3 2026: 27.4% year on year. source (Financials) →
!
Return on equity 2.1% with a 2.3% net margin: weak profitability. source (Key Stats) →
What to check before deciding
?Why is it priced above its peers, and is that premium justified?
?Is the revenue decline temporary or structural?
?What would lift profitability, and how soon?
What the analysis found
!
Valuation vs peers
P/E 103.97 is well above the Chemicals median of 18.46 (26 listed peers): priced richer than peers. source →